ANIK
$14.51
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
Intraday
Recent News
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company’s strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line growth, a differentiated hyaluronic acid-based technology platform,
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: Strong International Growth and ...
Anika Therapeutics Inc (ANIK) reports robust revenue growth and improved margins, despite facing regulatory and pricing challenges in Q4 2025.
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika (ANIK) delivered earnings and revenue surprises of +1,450.00% and +6.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics Q4 Earnings Call Highlights
Anika Therapeutics (NASDAQ:ANIK) detailed its fourth-quarter and full-year 2025 results and outlined its strategy for 2026 during its earnings call on Thursday, highlighting commercial-channel growth, progress on its hyaluronic acid (HA)-based pipeline, and operational initiatives aimed at improving
Anika: Q4 Earnings Snapshot
The Bedford, Massachusetts-based company said it had profit of 2 cents per share. Earnings, adjusted for stock option expense and to account for discontinued operations, came to 31 cents per share. The medical technology company posted revenue of $30.6 million in the period.